
    
      This is a single arm, open-label, single-center study. This study is indicated for elderly
      patients with CD19+ non-Hodgkin's lymphoma. The selections of dose levels and the number of
      subjects are based on clinical trials of similar foreign products. 36 patients will be
      enrolled. Primary objective is to explore the safety, main consideration is dose-related
      safety.
    
  